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Abstract
Background—Poor retention in HIV care is associated with worse clinical outcomes and 
increased HIV transmission. We examined the relationship between self-reported alcohol use, a 
potentially modifiable behavior, and retention.
Methods—9,694 people living with HIV (PLWH) from 7 participating U.S. HIV clinical sites 
(the CFAR Network of Integrated Clinical Systems (CNICS)) contributed 23,225 observations 
from January, 2011 to June, 2014. The retention outcomes were 1) Institute of Medicine (IOM) 
retention: 2 visits within 1 year at least 90 days apart and 2) visit adherence (proportion of kept 
visits / (scheduled + kept visits)). Alcohol use was measured with AUDIT-C, generating drinking 
(never, moderate, heavy) and binge frequency (never, monthly/less than monthly, weekly/daily) 
categories. Adjusted multivariable logistic models, accounting for repeat measures, were 
generated.
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Results—82% of our sample was male, 46% white, 35% black, and 14% Hispanic. At first 
assessment, 37% of participants reported never drinking, 38% moderate, and 25% heavy, and 89% 
of the patients were retained (IOM retention measure). Participants’ mean (SD) visit adherence 
was 84% (25%). Heavy alcohol use was associated with inferior IOM defined retention (adjusted 
OR (aOR) 0.78, 95% CI 0.69, 0.88), and daily/weekly binge drinking was associated with lower 
visit adherence (aOR=0.90, 95% CI 0.82, 0.98).
Conclusions—Both heavy drinking and frequent binge drinking were associated with worse 
retention in HIV care. Increased identification and treatment of heavy and binge drinking in HIV 
clinical care settings may improve retention in HIV care, with downstream effects of improved 
clinical outcomes and decreased HIV transmission.
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HIV clinical care; retention; adherence; alcohol use
Introduction
The benefits of antiretroviral therapy (ART) for improving clinical outcomes and prolonging 
life in persons living with HIV (PLWH)1–3 and in reducing HIV transmission to HIV-
uninfected individuals4 are well-known. To maximize ART benefit, patients must both 
access and remain fully engaged in HIV care. The HIV care continuum describes a series of 
steps necessary to achieve and maintain HIV suppression.5–8 These steps include HIV 
testing and diagnosis, linkage to care, retention in care, ART prescription, ART adherence 
and HIV RNA suppression. Successful retention in care allows patients to reap the benefits 
of therapy; however, retention in care in the U.S. is suboptimal, with less than 25% of all 
PLWH patients’ infection stably suppressed on ART, as over 50% of diagnosed persons fail 
to establish or remain engaged in medical care.5
”Heavy” or “at-risk” drinking, the quantity or pattern of alcohol use that confers increased 
risk for adverse health consequences,9,10 is defined by the National Institute of Alcohol 
Abuse and Alcoholism as drinking > 4 drinks per day or > 14 drinks per week in men, and > 
3 drinks per day and > 7 drinks per week in women. Heavy alcohol use is prevalent among 
PLWH11,12 and is associated with worse antiretroviral adherence13,14 and adverse 
therapeutic and clinical outcomes, including lack of viral suppression.15 Both moderate and 
heavy alcohol use have been associated with increased mortality among PLWH16–20 There 
are limited data on whether alcohol use influences retention in HIV care. Two large studies 
examining trends in retention examined the associations between multiple demographic, 
HIV risk factor, clinical variables, and retention, however, did not include information 
regarding substance use or mental health symptoms immediately prior to the retention 
interval.6,21 Among studies that have examined the association between alcohol use and 
establishment of and/or retention in care, results have been mixed, with some studies 
showing a trend towards worse retention among individuals with alcohol use disorders22 and 
others showing no difference.23,24 These studies have varied in the manner in which they 
assess alcohol use, using medical chart abstraction22,24 or patient self-report with the 
Addiction Severity Index tool.23 They have also used different measures for retention in HIV 
care based on completed clinic visits22,24 or patient’s report of having an HIV doctor and/or 
Monroe et al. Page 2
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
receiving ART.23 Finally, heavy alcohol use has been associated with receipt of lower 
quality HIV care as measured by HIV quality indicators abstracted from the medical record 
of patients in the Veterans Aging Cohort Study (VACS).25 One of the quality indicators was 
the Institute of Medicine (IOM) retention in care measure (attending at least two visits for 
HIV care separated by at least 90 days in a 12-month period), and heavy alcohol use was 
associated with worse retention in care.26
Several metrics based on missed and kept HIV primary care visits have been proposed to 
measure retention.5,26,27 The various measures reflect different behaviors and may be 
influenced by different factors. The IOM retention measure, based on visits kept by patients 
within a year, reflects whether the patient is able to complete a minimal number of visits that 
would indicate continuity of care at the clinic site. The visit adherence measure, which 
incorporates visit “no shows,” may reflect less engagement in care, and no-show visits have 
been associated with increased mortality.28
The primary aim of our study was to investigate the relationship between patient-reported 
alcohol use and retention in HIV care. We measured alcohol use with a standardized 
screening instrument to generate both heavy and binge drinking variables29,30 and measured 
retention in HIV care using both the IOM retention measure and the visit adherence 
measure. We hypothesized that compared to no alcohol use, patient-reported heavy and 
binge alcohol use would be associated with worse retention in care, independent of drug use 
and mental health symptoms.
Methods
This was a longitudinal study of HIV-infected patients receiving primary care services at any 
of seven Center for AIDS Research Network of Integrated Clinical Systems (CNICS) sites, a 
multisite clinical cohort study of PLWH.31
Study Population
CNICS is a research network consisting of diverse academic clinical sites across the United 
States and longitudinally collects clinical data on patients living with HIV. Seven 
participating CNICS sites were included in this analysis: Fenway Health/Harvard University, 
Johns Hopkins University, University of Alabama at Birmingham, the University of 
California San Diego, the University of California at San Francisco, the University of North 
Carolina Chapel Hill, and the University of Washington. All sites have Institutional Review 
Board approval, and all participants at each site sign informed consent.
Inclusion Criteria
Study participants were PLWH ≥ 18 years old who completed a 10–12 minute tablet-based 
clinical assessment of self-reported alcohol, drug, and mental health symptoms between 
January, 2011 and June, 2014 (referred to as “assessment” hereafter) allowing a minimum of 
12 months of follow up time. The assessment is intended to be completed by patients 
approximately every 6 months. For this analysis, we included all assessments with a 
completed alcohol instrument and we allowed for more than one assessment per patient. Our 
inclusion date ended in June 2014 so that we had at least one year of follow up visit data 
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available. We excluded observations from patients who 1) died within 1year of the 
assessment 2) completed an assessment but did not have a single HIV primary care visit on 
the day of the assessment or within a year of the assessment 3) had missing values on sex 
and race.
Data Source
CNICS captures clinical data for PLWH patients in care at each site, with standardized 
diagnosis, medication, laboratory, visit, and demographic information collected through 
electronic health records and other institutional data systems. Quality assessment of the data 
is conducted at the sites prior to data transmission and at the time of submission to the 
CNICS Data Management Core, and data undergo extensive quality assurance procedures 
after submission.31
Setting
The CNICS sites differ in terms of Screening, Brief Intervention, and Referral to Treatment 
(SBIRT) practices and practices to improve retention in care (See Table, Supplemental 
Digital Content 1, describing use of AUDIT-C, retention in care practices, and SBIRT 
practices for each site). All sites administer the AUDIT-C as part of a battery of 
questionnaires for research, however, some sites also make these results available to 
providers.
Outcomes
Following each assessment, the two primary outcomes were based on administrative records 
including documentation of scheduled and kept HIV primary care (not urgent care) visits. 
The IOM retention measure is defined as attending two or more HIV primary care visits 
separated by ≥90 days during a 12-month period. The visit adherence measure is defined as 
the proportion of kept HIV primary care visits compared to the total number of visits (kept 
visits/ (kept visits + scheduled visits)) during a 12- month interval.26
Measures of Interest
Alcohol use was assessed using the Alcohol Use Disorders Identification Test-C (AUDIT-
C).29,30 We examined alcohol use over the past 12 months two ways in our main analysis: 
drinking category and binge frequency category. In the drinking category, quantity and 
frequency of alcohol use was categorized as none, moderate (AUDIT-C score >0 and <3 for 
women or >0 and <4 for men), or heavy drinking (AUDIT-C score of ≥3 for women and ≥4 
for men) using the first three questions of the AUDIT-C. Binge frequency was examined 
separately, using the third question of the AUDIT-C, which captures the frequency of binge 
drinking in men (binge defined as ≥5 drinks per drinking episode) and women (binge 
defined as ≥ 4 drinks per drinking episode) using the following categories: never, less than 
monthly/monthly, or daily/weekly. Binge drinking category is often a subset of heavy 
drinking because of the way the questionnaire is structured, however we decided to look at 
the two measures separately to examine whether a binge pattern of alcohol use in itself was 
associated with retention.
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Additional covariates of interest included depressive and panic symptoms32,33 and illicit 
drug use (all collected by tablet-based clinical assessment),34,35 clinical site, race/ethnicity, 
age, calendar year, time from enrollment in CNICS to completion of assessment, CD4 
category (≤200, 201–499, ≥500 cells/mm3), viral load category (undetectable defined as 
≤200 copies/mL) (lab values within up to 180 days in advance of or 15 days after the 
assessment) and a combined sex/sexual HIV transmission risk factor variable. Patient 
demographic characteristics (age, race, and sex) and sexual HIV transmission risk factor 
were collected at the time patient began care at the clinical site. Men who have sex with men 
(MSM) as reported sexual HIV transmission risk factor was combined with sex to form three 
categories: female, male (did not report MSM), and male (reported MSM). Self-reported 
injection drug use (IDU) as an HIV transmission risk factor was categorized as present or 
absent. The sex/sexual risk factor variable and IDU risk factor variable were adjusted for 
separately in our models. Detailed description of study variables is provided in 
Supplemental Digital Content 2.
Statistical Analysis
We compared demographic and clinical characteristics by drinking category using chi-
square tests for categorical measures; and analysis of variance or Kruskal-Wallis test for 
continuous measures, as appropriate.
To examine the relationship between alcohol use and HIV retention in care we fit 
multivariable logistic regression models, using the IOM retention measure as a dichotomous 
outcome. To estimate the relationship between alcohol use and the visit adherence measure, 
we fit a generalized linear model (GLM) with binomial error and a logit link. In both cases 
we used generalized estimating equations to account for repeat measures using an 
exchangeable correlation structure and report robust standard errors.
In the final data including 23225 observations among 9694 unique patients, 78% had 
complete data. Missing data was present for alcohol binge drinking, panic and depression 
symptoms, illicit drug use, sex-MSM variable, IDU history, CD4 cell count and HIV RNA 
level. We used multiple imputation for the missing data, fitting models including all study 
demographic and clinical variables, and time-updated measures were lagged to the prior 
assessment as indicated. The final covariates in the model included drinking category or 
binge frequency category, current drug use, panic symptoms, depression screen, sex/sexual 
risk factor combination variable, age, race, injection drug use as HIV transmission risk 
factors, CD4 category, viral load category, enrollment date, and clinical site.
We evaluated the interaction terms generated from the combination of each alcohol variable 
with each mental health symptom variable.
Analyses were conducted using R Version 3.2.1 and a p-value <0.05 was considered 
statistically significant.
Results
A detailed description of study flow is provided in Supplemental Digital Content 3.
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Table 1 displays the demographic and clinical characteristics of participants at the time of 
each person’s initial assessment. Overall, 37% of patients reported never drinking, 38% 
reported moderate drinking, and 25% reported heavy drinking, while 69% reported never 
binge drinking, 25% reported binge drinking monthly or less than monthly, and 6% reported 
binge drinking daily or weekly.
The majority of participants (73%) had an undetectable viral load (≤200 copies/mL), and 
almost half had CD4 cell counts greater than ≥500 cells/mm3. The majority of the 
participants were male (82%), 46% of participants identified as white, 35% as black, and 
14% as Hispanic. Fifteen percent reported current drug use. Twelve percent of patients 
reported symptoms consistent with panic disorder, 14% reported some panic symptoms, and 
70% reported no panic symptoms. Twenty-one percent screened positive for depressive 
symptoms.
Male-MSM and white participants were more likely to report moderate and heavy alcohol 
use in comparison to no use, with men who reported sex with men as their HIV risk factor 
comprising a larger proportion (73% of each group) of moderate and heavy alcohol drinkers 
and a lower proportion (51%) of persons with no alcohol use (51%). Similarly, a higher 
proportion of moderate and heavy drinkers were white (62 and 59%, respectively) compared 
with the proportion of non-drinkers who were white (50%). There were more current drug 
users in the heavy alcohol group compared to the moderate and no alcohol groups.
In the year following their first assessment, 89% of the patients were retained (IOM 
retention measure), and participants’ mean (SD) visit adherence was 84% (25%).
IOM retention measure
Table 2 (left columns) shows the separate regression models for the IOM retention measure:. 
one fit with the drinking category (none, moderate, heavy) and the other fit with the binge 
frequency category. Heavy drinking was associated with worse retention (OR=0.78, 95% CI 
0.69, 0.88). Moderate alcohol use was not significantly associated with retention in care (OR 
= 0.93, 95% CI 0.83, 1.03). Using binge frequency as a predictor, monthly or less binge 
drinking (OR= 0.89, 95% CI 0.80–0.99) was associated with worse retention compared to no 
binge drinking. Daily/weekly binge drinking was not significantly associated with retention 
in care (OR = 0.90, 95% CI 0.74, 1.10)
Current drug use was not significantly associated with worse retention for the alcohol 
drinking category model (OR=0.88, 95% CI 0.77, 1.00) but was significantly associated with 
worse retention in the binge frequency model (OR= 0.87, 95% CI 0.76, 0.99). Depressive 
symptoms were associated with improved retention (OR= 1.15, 95% CI 1.02, 1.30), while 
panic symptoms were not associated with retention.
Visit adherence measure
Table 2 (right columns) shows the separate regression models for the visit adherence 
measure: one fit with the drinking category (none, moderate, heavy) and the other fit with 
the binge frequency category. There was no association between moderate or heavy drinking 
and visit adherence. However, daily/weekly binge drinking was associated with worse visit 
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adherence (OR= 0.89, 95% CI 0.80, 0.99). The OR of 0.89 represents an 11% decrease in 
the odds of attending a scheduled appointment. Current drug use was associated with worse 
visit adherence (OR=0.74, 95% CI 0.69, 0.79 for the drinking category model and OR=0.74, 
95% CI 0.70, 0.79 for the binge frequency category model). In contrast to the IOM retention 
measure models, panic symptoms and depressive symptoms were associated with worse visit 
adherence, with OR ranging from 0.85 to 0.93.
An expanded table showing the association between other demographic and clinical 
characteristics and the IOM retention measure and visit adherence is shown in Supplemental 
Digital Content 4. Of note are the associations between Black race and worse visit adherence 
(OR=0.63, 95% CI 0.58, 0.68 in the model with drinking categories) and the associations 
between higher CD4 count and worse visit adherence (OR=0.82, 95% CI 0.82, 0.92 in the 
model with drinking categories)
We evaluated the interaction terms generated from the combination of each alcohol variable 
with each mental health symptom variable and none of them were statistically significant at 
the level of α = 0.05.
Discussion
Among a large sample of PLWH, alcohol use independent of both current drug use and 
panic/depressive symptoms was associated with worse retention in care assessed by two 
retention measures. Among the alcohol variables, the strongest observed association was 
between heavy drinking and worse retention by the IOM retention measure. Binge drinking 
was also associated with worse retention, but not consistently across the different retention 
outcomes measured and at the different levels of the binge frequency variable. Our findings 
imply that identifying and treating individuals with heavy and binge drinking would 
potentially improve retention in HIV care.
Retention in care is crucial for provision of ART. Early, consistent ART prolongs life due to 
decreased opportunistic infections and decreased incidence of non-AIDS related 
conditions.36 Worse retention has been associated with worse clinical outcomes in multiple 
studies. For example, among patients in South Carolina, patients who were optimally 
retained after originally being linked to care had a larger decrease in viral load, increase in 
CD4 cells, and lower mortality.37 A variety of retention measures have shown an association 
between worse retention and lower likelihood of viral load suppression.28 Among Veterans 
Administration (VA) patients, worse retention, measured by number of quarters in a year 
with a completed visit following a new HIV diagnosis, was associated with mortality. 
Finally, missed visits, even among patients who appear to be retained by the IOM core 
indicator, have been shown to be a marker of mortality. Clearly, retention has a large role in 
people’s overall HIV outcomes, and modifiable factors which can improve retention should 
be targeted for intervention.
We used multiple parameterizations of alcohol in this analysis. In a clinical setting, a 
commonly used alcohol instrument is the AUDIT-C, which generates both a drinking 
category and a binge frequency category. We were interested to see how retention outcomes 
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varied by classification of alcohol use. Heavy drinking was associated with worse retention 
by the IOM measure, suggesting an impairment of functioning among heavy drinkers who 
were not able to keep even two visits per year. Our finding that daily/weekly binging was 
associated with worse visit adherence (indicating more “no-shows”), may reflect a tendency 
among individuals who binge drink to miss visits because of adverse short-term 
consequences of their binge use, such as having a hangover. When heavy or binge drinking 
is detected on the AUDIT-C, it would be a signal to clinicians that the patient is at risk for 
worse retention, among other undesirable outcomes. Knowing that the patient is a heavy or 
binge drinker might compel the provider to guide patient towards services to reduce alcohol 
use, including brief intervention, which has been shown to be effective among women living 
with HIV,38 Additional evaluation of and treatment for alcohol use disorder, with more 
intense counseling or pharmacotherapy, may also be warranted.
Prior studies of retention have not always captured current alcohol use,6,21 and results 
regarding the alcohol-retention association have been mixed. In one study, alcohol use, 
captured through chart abstraction of presence or absence of alcohol use, was not 
significantly associated with establishing care (visit within the first 6 months of diagnosis).22 
In a VA study by Giordano et al, veterans with alcohol abuse (captured by ICD-9) were as 
likely to be retained (retention defined as one visit in each quarter) as those without a 
diagnosis of alcohol abuse.39 In contrast, our study demonstrated a significant association 
between heavy and binge alcohol use and worse retention. In the VA study, the ICD-9 
diagnosis of alcohol abuse indicates a diagnosis by a clinician. VA patients identified by 
clinicians as having alcohol abuse may have access to enhanced alcohol treatment services, 
which may in part explain the lack of association between alcohol use and retention in that 
study.
Differences between our results and those of other studies may stem from differences in how 
alcohol exposure was measured. In CNICS, patients participate in a self-report tablet-based 
assessment using the AUDIT-C. The use of this standardized instrument may identify more 
individuals with heavy alcohol use than medical record abstraction based on clinician 
documentation of patient alcohol use. Physician suspicion of heavy drinking has been shown 
to have a low sensitivity (27%) for detecting heavy alcohol use.40 Moreover, self-assessment 
using a computer may overcome the social desirability bias that might make PLWH with 
alcohol use disorders reluctant to disclose their problem. In addition, the differences in 
retention measures among studies may also in part explain differences in study findings. 
Finally, our study captured individuals at various stages of their HIV care, not only people 
originally establishing care thus may be more generalizable to all patients in HIV care.
Our findings emphasize that retention in HIV care is affected by the presence of heavy 
alcohol use, independent of drug use and mental health symptoms. Clinics must enhance 
their capacity to identify individuals with alcohol use, drug use, and mental health disorders, 
and have comprehensive treatment available. Identification of these issues in real time may 
allow for more efficient referrals and higher uptake of substance use and mental health 
treatment. In busy clinics, the AUDIT-C can be administered rapidly. The AUDIT-C is in use 
clinically at some of the CNICS sites included in this analysis and has been incorporated 
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into care at Veterans Affairs clinics.41 Retention measures can be calculated quickly from 
visit data to monitor both individual-level and clinic-level outcomes.
Evidence-based guidelines from a panel convened by the International Association of 
Physicians in AIDS Care to improve retention include substance use treatment and 
depression screening and treatment.42 Enhanced personal contact between patients and 
clinic staff led to improvement in retention in one recent trial,43 however, no benefit was 
demonstrated when patients who reported illicit drug use were analyzed separately. The 
authors noted that enhanced services for illicit drug users may be required to improve 
retention; we hypothesize that the same is true for individuals with heavy alcohol use. 
Screening for alcohol misuse as a preventive measure has been ranked as a grade B from the 
USPSTF, and the Affordable Care Act (ACA) requires coverage of preventive services 
graded A or B by the USPSTF.44 The Affordable Care Act requires that insurance provided 
through the exchanges and by Medicaid must cover substance use disorder treatment, 
leading to increased availability of treatment services among those in whom a disorder is 
detected.45 Additionally, substance use screening is one of the core measures for the HRSA 
HIV/AIDS Bureau. Despite these strong recommendations and coverage for services, 
alcohol screening is still not routinely performed. Strengths of our study include our large 
and geographically diverse sample size and our ability to capture self-reported substance use 
in real time using validated measures. Limitations of the study include the lack of long-term 
clinical outcomes and the exclusion of individuals who had an assessment but no HIV 
primary care visit. We were unable to determine which patients are receiving treatment for 
alcohol use and what impact that has on retention. Additionally, we were unable to 
determine if patients switched to a clinic outside of CNICS. Next, there was a small amount 
of missing data, which we addressed by imputing missing values when at least one variable 
was missing from an observation, basing these imputed variables both on prior responses by 
the patient (if available) and other demographic and clinical variables. In this analysis, we 
cannot account for the current trend in HIV practice to see stable patients less frequently, 
however, we limited the study period to a short time frame to minimize period effects. In 
addition, patients who are heavy drinkers may be less likely to complete the assessments 
than patients who are not heavy drinkers and those same patients may be less likely to be 
retained. Despite that possibility, we still found an association between alcohol and worse 
retention even though some heavy drinkers may not have been included. Another limitation 
is that we were unable to adjust for severity of medical illnesses other than HIV. An 
additional potential limitation is limited generalizability, as CNICS sites are may not be 
representative of HIV care delivery within the U.S. Prior work by Lesko et al examined 
whether the effect of ART on all-cause mortality determined using CNICS data was 
generalizable to the U.S. population living with HIV.46 Similar effects of ART on mortality 
were found with the CNICS population and by extrapolating the findings to the general 
population living with HIV. Although we have not specifically examined the relationship of 
alcohol to retention using our findings extrapolated to the general population, we believe that 
the diversity of the clinics within the CNICS is representative of PLWH in the US overall. 
Also with regards to generalizability, CNICS represents a cohort of individuals generally 
engaged in clinical care; our generalizability is therefore limited to people who are engaged 
in HIV care. Even within that context, we see an effect on alcohol on retention, and we 
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emphasize its importance as a modifiable risk factor for worse retention. Finally, as this is a 
longitudinal cohort study, we are unable to account for unmeasured confounders and cannot 
infer causality. Our future work in this area will move beyond the association between heavy 
alcohol use and retention in care to examine the relationships between heavy alcohol use and 
both ART initiation and ART adherence.
In conclusion, we found that heavy alcohol use was associated with worse retention, 
independent of mental health and substance use disorders. Increased identification and 
treatment of heavy and binge drinking in HIV clinical care settings, by screening for alcohol 
use at all HIV primary care visits, may potentially improve retention in HIV care, with 
downstream effects of improved clinical outcomes and decreased HIV transmission.
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Table 2
Association between alcohol and retention‡
IOM RETENTION MEASURE VISIT ADHERENCE MEASURE
Drinking
Categories
Binge Frequency
Categories
Drinking Categories Binge Frequency
Categories
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Drinking Category
  Never Ref Ref Ref Ref
  Moderate 0.93 (0.83, 1.03) -- 1.01 (0.96, 1.07) --
  Heavy*** 0.78 (0.69, 0.88)** -- 0.97 (0.91, 1.04) --
Binge Frequency
Category
  Never Ref Ref Ref Ref
  ≤ monthly -- 0.89 (0.80, 0.99)* -- 0.98 (0.93, 1.03)
  Daily/weekly -- 0.90 (0.74, 1.10) -- 0.90 (0.82,0.98)*
Current Drug Use
  Yes (vs. No) 0.88 (0.77–1.00) 0.87 (0.76, 0.99)* 0.74 (0.69–0.79)** 0.74 (0.70, 0.79)**
Panic Symptoms
  None Ref Ref Ref Ref
  Some 0.94 (0.83, 1.08) 0.94 (0.82, 1.07) 0.96 (0.91, 1.02) 0.96 (0.91, 1.02)
  Panic Disorder 0.92 (0.80, 1.07) 0.92 (0.80, 1.07) 0.85 (0.80, 0.90)** 0.85 (0.80, 0.90)**
Depression Screen
  Positive (vs.
Negative) 1.15 (1.02, 1.30)
* 1.15 (1.02, 1.30)* 0.92 (0.88, 0.97)* 0.92 (0.88, 0.97)*
*p<0.05
**p<0.0001
***
Heavy = AUDIT-C > 3 for women or > 4 for men
‡
“Four different models were fit for each retention measure and drinking exposure type reported. Each model was adjusted for age, race, sex/sexual 
risk factor, CD4 category, viral load category, enrollment date, site, IVDU as HIV risk factor
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